News | January 21, 2026
Senores Pharmaceuticals reports stellar Q3 FY26 growth; PAT surges 105%
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Over 8.8?million Indians aged 60 and above currently live with dementia,
India in the Changing Landscape of Life-Sciences Research & Development
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society
Subscribe To Our Newsletter & Stay Updated
